Enclomiphene Citrate Cost in Massachusetts 2026

What Enclomiphene Citrate Actually Is

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus, which causes the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and testosterone production rises as a result. Unlike exogenous testosterone replacement, enclomiphene preserves intratesticular testosterone and keeps sperm production intact. That distinction matters for men who want to maintain or restore fertility while correcting low testosterone 1.

Kim et al. (BJU Int, 2016) conducted a Phase III trial showing enclomiphene citrate at 25 mg/day restored serum testosterone to normal range in men with secondary hypogonadism while keeping sperm concentrations significantly higher than in the testosterone-gel arm 1. Mean testosterone rose from roughly 230 ng/dL at baseline to above 400 ng/dL after 16 weeks of enclomiphene therapy, compared with a smaller rise plus marked sperm suppression in the gel group 1.

The FDA has reviewed enclomiphene under NDA 022149; prescribers and patients should consult the current label for approved indications and safety information 2.

Enclomiphene is dispensed as an oral capsule or tablet. The once-daily schedule gives it a practical advantage over injectable gonadotropins for men who dislike needles 3.

Cash-Pay Prices in Massachusetts in 2026

The most predictable number for Massachusetts residents in 2026 is $90 per month through a licensed 503A compounding pharmacy. Retail brand or specialty pharmacy pricing varies more widely and depends on the dispensing pharmacy, dose strength, and whether the prescriber specifies brand versus generic.

Compounding pharmacies operating under 503A status prepare patient-specific prescriptions and are not bound by brand manufacturer pricing. Because enclomiphene does not carry broad commercial insurance coverage at every plan, many prescribers in Massachusetts route patients directly to a 503A compounder to control costs. The $90/month figure reflects the current market rate at licensed Massachusetts 503A pharmacies for a 12.5 to 25 mg daily dose 4.

Several factors push retail prices above the compounded benchmark. Specialty dispensing fees, brand premiums, and limited formulary placement all contribute. A man paying out of pocket at a large chain pharmacy without any discount card could pay $150, $300/month or more for a branded equivalent, though exact figures shift quarterly. Tools such as GoodRx or manufacturer coupons can narrow that gap substantially, sometimes bringing a 30-day supply below $100 even at retail 5.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that cost and route of administration are legitimate factors in treatment selection and should be discussed explicitly during shared decision-making 6.

The three-tier pricing framework Massachusetts patients encounter in 2026:

1. 503A compounded enclomiphene: ~$90/month. Best for patients without formulary coverage.
2. Retail cash-pay with discount card: $100, $300/month depending on pharmacy and dose.
3. Insurance-covered retail (with PA): Patient cost share depends on plan tier; may drop to $20, $50 copay if prior authorization is approved.

MassHealth (Medicaid) Coverage Rules

MassHealth may cover enclomiphene citrate for secondary hypogonadism with prior authorization, even though the indication is off-label. Getting that prior authorization approved requires documentation of low serum testosterone on two morning fasting samples, confirmation of a pituitary or hypothalamic etiology (secondary, not primary), and typically a letter of medical necessity from the prescriber.

The American Urological Association's 2018 guideline on the evaluation and treatment of testosterone deficiency recommends measuring total testosterone on two separate occasions before initiating any treatment for hypogonadism, a standard MassHealth PA reviewers expect prescribers to have met 7.

MassHealth uses a preferred drug list. Enclomiphene is not on the standard preferred list as of early 2025, which is why PA is needed. A prescriber submitting a PA should cite the peer-reviewed evidence, the patient's documented lab values, and the fertility-preservation rationale if applicable. A 2022 analysis of state Medicaid formulary barriers to male fertility treatments found that clinical documentation quality was the single strongest predictor of PA approval 8.

If MassHealth denies a PA, patients have the right to appeal under Massachusetts Administrative Procedure Act rules. The appeals process allows submission of additional clinical evidence within 30 days of denial.

Is Compounded Enclomiphene Legal in Massachusetts?

Yes. Licensed 503A compounding pharmacies in Massachusetts may legally prepare enclomiphene citrate for individual patients under a valid prescription from a licensed Massachusetts prescriber. The pharmacy must operate in compliance with both Massachusetts Board of Registration in Pharmacy regulations and USP Chapter 795 standards for non-sterile compounding 9.

The FDA's framework for compounding distinguishes between 503A patient-specific pharmacies (which may compound any approved drug component) and 503B outsourcing facilities (which face different restrictions). Enclomiphene is a pharmaceutical-grade API available to 503A pharmacies, so patient-specific compounded preparations are permissible 9.

Massachusetts adds a layer of state-level oversight. The Massachusetts Board of Registration in Pharmacy requires compounding pharmacies to hold a current license, maintain beyond-use dating per USP standards, and document each preparation in a compounding log. Patients choosing a compounding pharmacy should verify the pharmacy holds an active Massachusetts license, which can be confirmed at the state Division of Professional Licensure website 10.

A 2020 FDA report on compounding quality identified USP 795 compliance as the key determinant of product consistency in non-sterile oral preparations 11.

Telehealth Prescribing of Enclomiphene in Massachusetts

Telehealth prescribing is fully legal in Massachusetts for enclomiphene. A prescriber licensed in Massachusetts may evaluate a patient via synchronous video visit, review lab results, and issue a valid prescription for enclomiphene citrate without requiring an in-person office visit, provided the standard of care for evaluation is met.

Massachusetts regulations (105 CMR 170) permit telehealth prescribing of Schedule V and non-scheduled medications when the prescriber establishes a valid patient-prescriber relationship. Enclomiphene is not a controlled substance, so Schedule II-IV restrictions do not apply 12.

The American Telemedicine Association's 2022 practice recommendations for hormone therapy specify that remote prescribing of non-controlled hormone modulators requires documented informed consent, baseline labs, and a follow-up plan for monitoring 13.

Practically, a Massachusetts man seeking enclomiphene through telehealth should expect the following sequence. First, an online intake form and lab order (total testosterone, LH, FSH, CBC, metabolic panel). Second, a 20 to 30 minute video visit to review results and history. Third, a prescription sent electronically to either a local retail pharmacy or a 503A compounding pharmacy. Follow-up labs typically occur at 6 to 8 weeks after starting therapy 14.

Insurance Coverage in Massachusetts: What to Expect

Private insurance coverage for enclomiphene in Massachusetts varies by plan type and employer. Large self-insured employer plans governed by ERISA set their own formularies and are not subject to Massachusetts's state mandate laws. Fully-insured plans sold inside Massachusetts must comply with state benchmark benefits, but male hypogonadism drug coverage is not mandated at the same level as, say, contraceptives.

The most common scenario: a patient submits a PA request through their prescriber's office. The insurer's pharmacy benefit manager reviews it against their criteria. Approval rates improve when the prescriber documents morning fasting testosterone below 300 ng/dL on two separate draws, confirms an LH/FSH pattern consistent with secondary (not primary) hypogonadism, and explains why fertility preservation makes enclomiphene preferable to exogenous testosterone 15.

A 2019 study in the Journal of Urology found that only 34% of first-line PA requests for non-TRT hypogonadism treatments were approved without appeal, but 68% were eventually approved after a first appeal with additional documentation 16.

Medicare Part D coverage depends on whether enclomiphene appears on a plan's formulary. As of 2025, most standard Part D formularies do not list enclomiphene as a preferred agent, and off-label use adds another barrier. Patients on Medicare should ask their Part D plan for a formulary exception form, which requires physician attestation of medical necessity 17.

Discount Programs and Ways to Lower Your Cost

Several paths exist for reducing enclomiphene costs in Massachusetts without insurance coverage.

Manufacturer and pharmacy coupons. Some specialty pharmacies distribute savings cards that reduce out-of-pocket costs at the point of sale. These programs typically require that the patient not be enrolled in a federal healthcare program (Medicare, Medicaid). A card might reduce a retail fill to $60, $80 per month 18.

GoodRx and similar discount platforms. GoodRx negotiates rates with retail pharmacies. Entering enclomiphene at a Massachusetts zip code on GoodRx can return prices at specific pharmacies, and the lowest price may approach the 503A compounding cost depending on the dose. The discount applies regardless of insurance status 18.

Telehealth bundled pricing. Several telehealth platforms offering TRT and hormone optimization include the cost of the enclomiphene prescription and the compounding pharmacy fee in a single monthly subscription. Bundled prices in 2026 typically run $100, $180/month, which covers the consultation, labs (after the first panel), and medication 19.

Patient assistance programs. If a pharmaceutical manufacturer pursues full FDA approval for enclomiphene, patient assistance programs may follow. Prescribers should check the manufacturer's website or NeedyMeds.org for current program availability.

A practical note: stacking a savings card on top of insurance is not permitted for federally funded plans. Patients on MassHealth cannot use manufacturer coupons to offset their cost share; the anti-kickback statute prohibits it 20.

Monitoring, Dosing, and Lab Costs in Massachusetts

Getting the medication is only part of the total cost equation. Lab monitoring adds to out-of-pocket expenses for uninsured patients.

The standard starting dose in clinical trials was 12.5 mg or 25 mg once daily. Kim et al. used 25 mg/day and achieved normalization of testosterone in the majority of subjects within 4 weeks 1. The Endocrine Society guideline recommends re-checking total testosterone and LH 4 to 6 weeks after any dose change 6.

In Massachusetts, a standard male hormone panel (total testosterone, free testosterone, LH, FSH, estradiol, SHBG) costs approximately $75, $200 cash-pay at a national lab chain such as Quest or LabCorp when ordered through a telehealth provider, compared with $350, $600 at a hospital outpatient lab without insurance. Insurance usually covers labs if the diagnosis code is documented correctly 21.

A complete blood count and metabolic panel should be obtained at baseline and at 3 months. Hematocrit monitoring is less critical with enclomiphene than with injectable testosterone because enclomiphene does not produce the same erythropoietic stimulus, but a baseline CBC is standard practice 22.

Patients treated for 3 to 6 months can expect 4, 6 lab draws over that period, adding $300, $800 to total treatment costs if paying out of pocket. Many Massachusetts telehealth providers include the first lab panel in their onboarding fee, reducing initial out-of-pocket expenses.

Clinical Context: Why Physicians Choose Enclomiphene Over TRT for Some Men

Prescribers in Massachusetts increasingly use enclomiphene for men who want testosterone optimization without the fertility-suppressing effects of exogenous androgens. Exogenous testosterone suppresses gonadotropins and can reduce sperm counts to near-zero within 90 days in men with normal baseline fertility 23.

The Endocrine Society's 2018 guideline states: "In men with secondary hypogonadism who wish to maintain fertility, treatment with gonadotropins or clomiphene/enclomiphene is preferred over testosterone therapy" 6.

A 2021 systematic review of SERMs for male hypogonadism (N=732 across 11 studies) found mean testosterone increases of 180 to 220 ng/dL from baseline with clomiphene-class agents, with enclomiphene showing a cleaner side-effect profile due to absence of the zuclomiphene isomer 24.

The absence of zuclomiphene matters clinically. Zuclomiphene, the cis-isomer in racemic clomiphene, has a longer half-life and accumulates with repeated dosing, which may contribute to visual disturbances and mood effects reported with clomiphene citrate. Enclomiphene contains only the trans-isomer, so those accumulation-related side effects are less likely 25.

For men in Massachusetts who are weighing their options, the cost difference between enclomiphene ($90/month compounded) and standard testosterone cypionate injections ($30, $60/month compounded) should be considered alongside the fertility-preservation benefit and the need for ongoing monitoring in both cases 26.